AAD 2026: Survey Highlights Facial Concerns Among GLP-1 Weight Loss Patients

A large survey presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, Colorado, highlights evolving aesthetic concerns among patients receiving glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss. The analysis, based on responses from 406 US healthcare providers (HCPs), offers insight into a rapidly expanding patient population in aesthetic practice.

According to the survey, the number of patients receiving GLP-1 RA therapies increased substantially between 2023 and 2024 across all specialties, with some groups reporting increases exceeding 100%. These patients were most commonly described as female (70%), White (64%), and aged 30 to 49 years.

HCPs estimated that approximately 52% of GLP-1 RA–treated patients expressed concern about their facial appearance, including volume loss and skin laxity—features often associated with rapid weight loss. These changes, sometimes referred to as “Ozempic face,” have contributed to increased demand for aesthetic interventions.

Despite this interest, several barriers to treatment were identified. Cost was the most frequently cited concern, reported by more than 80% of HCPs across specialties. Fear of unnatural results (up to 70%) and uncertainty about treatment options were also commonly noted. Safety concerns and discomfort with injections were less frequently reported but remained relevant factors.

The survey also found that a substantial proportion of GLP-1 RA patients were new to aesthetic practices, suggesting an opportunity for practice growth. However, the authors noted that findings are based on provider-reported estimates rather than direct patient data, which may limit generalizability.

Overall, the results underscore the growing intersection between metabolic therapies and aesthetic dermatology, with implications for patient education and treatment planning.